Innodem Neuroscience’s ETNA-MS Receives Health Canada’s Approval for the Treatment of Multiple Sclerosis (MS)
Shots:
- The company received Health Canada’s approval for the Eye Tracking Neurological Assessment for Multiple Sclerosis (ETNA-MS) a software-turned-medical device (SaMD, Class II) developed to administer a non-invasive test and provide an EDSS score in the range between 1.0 & 4.5 to track disease progression in MS patients
- ETNA-MS functions by turning an iPad Pro into a medical device that performs tests in 10mins. through short videos designed to highlight the eye movement abnormalities as the patient performs several eye movement tasks. The eye movement parameters are extracted and combined through machine learning algorithms thereby providing an EDSS Score
- Innodem Neurosciences has collaborated with Novartis (Canada) to advance treatment for patients with MS across the globe
Ref: Newswire | Image: Innodem
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
